Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta

2023-503293-21-00 · tracked via the Priya Life Science EU tracker

Sponsor

Amgen Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Skin and Connective Tissue Diseases

Decision date

23/02/2026

Enrollment target

Sites

Germany, Hungary, Italy, Belgium, Austria, Slovakia, Spain

Condition studied

Osteogenesis Imperfecta

Investigational medicinal product(s)

EVENITY 105 mg solution for injection in pre-filled syringeEVENITY 105 mg solution for injection in pre-filled penEVENITY 105 mg solution for injection in pre-filled syringeEVENITY 105 mg solution for injection in pre-filled pen

Eligibility

Age group

0-17 years

Sex

Female, Male

Primary endpoint

Adverse events

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2023-503293-21-00 on CTIS ↗ ← All trials in the EU